VANDERBILT UNIVERSITY, BRIGHAM YOUNG UNIVERSITY, AND CERAGENIX PHARMACEUTICALS REPORT NOVEL DRUG COMPOUND KILLS MULTIPLE HIV STRAINS

Vanderbilt University, Brigham Young University and Ceragenix Pharmaceuticals, Inc. today announced that one of a family of compounds, called Ceragenins (or CSAs) shows potent virucidal activity in in vitro laboratory tests against multiple strains of Human Immunodeficiency Virus (HIV), the virus that causes AIDS.
Genetic Engineering News